





Kongeriget Danmark

Patent application No.: PA 1998 01500

Date of filing:

17 November 1998

Applicant:

Novo Nordisk A/S

Novo Allé

DK-2880 Bagsværd

This is to certify the correctness of the following information:

The attached photocopy is a true copy of the following information:



The specification, claims and figures as filed with the application on the filing date indicated above.

Patent- og Varemærkestyrelsen Økonomi- og Erhvervsministeriet

TAASTRUP 03 December 2002

Head Clerk

PATENT- OG VAREMÆRKESTYRELSE

15:45

HEIDEN & HOIBERG + 43588881

Modtaget PD

NR.819

NOV. 1998

P 228 DK 1

The present invention relates to a medication delivery device having a cartridge and a dosing assembly coupled together for delivering selected doses of medication, wherein at least one of the coupling means of the cartridge is unitarily moulded with the cartridge.

1

Background

Some medication, such as insulin is self-administered. The applical diabetes patient will require injections of insulin several times during the day. The required insulin dose will vary from patient to patient, and will for each patient often also vary during the day. Each patient will often establish a regimen for the insulin administration adjusted to his or her insulin need as well as lifestyle. Medication delivery pens have been developed to facilitate the self-administration of medication, such as insulin.

15

20

10

One prior art medication delivery pen includes a pen body assembly comprising a medication cartridge and a plunger device. A needle assembly may be connected to the pen body assembly. The medication is delivered by moving or pressing a plunger in the direction of the needle assembly thereby delivering the medication. When the medication in the cartridge is exhausted the pen body assembly is discarded. Depending on the medication needs for each individual the medication in the cartridge will last for several days. During this period the needle assembly will often have to be displaced by a new assembly or new needle due to increasing bluntness of the needle making injections painful for the patient.

25

More recent developments have revealed medication delivery pens, wherein the cartridge holder assembly can be disassembled from the per body assembly after the medication therein has been exhausted, discarded and replaced by a new medicine-containing cartridge assembly.

30

35

An example of this is shown in EP 0 688.671 disclosing a medication delivery pen having a rausable pen body assembly and a disposable cartridge assembly that are threadedly engageable with one another. The cartridge assembly comprises a cartridge, a cartridge housing, a cap between the distal end of the cartridge and the housing, securing the cartridge in the housing and being adapted for engagement

7-11-98

15:45 HEIDEN

HEIDEN & HOIBERG + 43506001

NR.019

85

2

with a needle assembly. Furthermore, the cartridge comprises a plunger within the cartridge. The reusable pen body assembly is coupled through a threaded coupling to the cartridge housing. Thus, the total number of parts camprising the prior art cartridge assembly is high.

5

It is an object of the present invention to provide a medication delivery device wherein the amount of parts of the cartridge is minimised.

Summary of the Invention

10

Accordingly, the present invention relates to a medication delivery device comprising a cartridge assembly, a dosing assembly and optionally a needle assembly.

said cartridge assembly having one end sealed with a pierceable sealing, said end of the cartridge assembly comprising coupling means for engaging a needle assembly, and another end comprising coupling means for engaging the dosing assembly, said cartridge assembly further comprising a cartridge wherein at least one of the coupling means of said cartridge assembly is unitarity moulded with the cartridge, the cartridge further comprising a stopper adapted to receive

20 plunger means, and

said dosing assembly comprising plunger means has coupling means for engaging the cartridge assembly, and said plunger means is adapted to engage the stopper of the cartridge when the dosing assembly is coupled to the cartridge.

25

30

35

The above-described medication delivery device has fewer parts that the prior art devices because at least one coupling means is moulded unitarily with the cartridge. Thereby the costs involved in the production and assembling of the device are reduced, and the device is more economical, which is an important feature for a disposable device.

The medical delivering device may either be manufactured as a disposable device which is sold pre-filled with the insulin or it may appear as a durable medical delivering device so designed that it can receive disposable cartridges with insulin.

10

15

20

25

30

.
17/11/98 15:45 HEIDEN & HOIBERS > 435888881 NR.819 88

3

In a preferred embodiment the dosing assembly is reusable and the carridge assembly is disposable, and accordingly, a second aspect of the present invention is a medication delivery device wherein the dosing assembly is releasably coupled to the cartridge assembly.

The medication delivery device is preferably constructed as to secure that the plunger means abute on the stopper during use of the device, such as attaching and releasing the needle assembly. It is understood that the plunger means must disengage the stopper when the cartridge assembly is deliberately released from a reusable dosing assembly because the medication in the cartridge has been exhausted and the cartridge assembly is to be discarded. In this situation the plunger means is to be retracted to the dosing assembly before assembling the device with a new cartridge assembly.

Securing the abutment of the plunger means on the stopper during use of the medication delivery device, in particular when the needle assembly is coupled to and/or decoupled from the cartridge assembly, may be carried out by a variety of means. In a preferred embodiment the abutment is secured by preventing the cartridge assembly from being inadvertently released from the dosing assembly.

In particular, when the cartridge assembly is released from the dosing assembly through a movement including an axial movement, such as through a threaded coupling, it is preferred that the means for releasably coupling the needle assembly and the cartridge assembly together are such that the coupling and/or decoupling of the needle assembly cannot cause an axial movement of the cartridge assembly with respect to the dosing assembly. Thus, in that respect examples of the preferred couplings between the needle assembly and the cartridge assembly include releasable snap locks. Another preferred embodiment includes a safety on the coupling between the dosing assembly and the cartridge assembly, such as hinge on the coupling or a threaded coupling releasable only after exerting an axial pressure on the coupling.

15:45

10

15

20

25

30

35

HEIDEN & HOIBERG + 43508001

NR.819

977

- --

A second aspect of the present invention is a cartridge assembly for use in a medication delivery device, said cartridge assembly having one end sealed with a pierceable sealing, said end of the cartridge assembly comprising coupling means for engaging a needle assembly, and another end comprising coupling means for engaging the dosing assembly, said cartridge assembly further comprising a cartridge wherein at least one of the coupling means of said cartridge assembly is unitarily moulded with the cartridge, said cartridge further comprising a stopper.

The cartridge assembly may further comprise a cartridge housing for protecting the cartridge in use. Furthermore, when the cartridge is moulded unitarily with one coupling means the cartridge housing may comprise the other coupling means. Accordingly, in one embodiment of the invention the housing of the cartridge assembly comprises coupling means for coupling the cartridge assembly to the dosing assembly, preferably the coupling means is moulded unitarity with the housing. The cartridge is arranged within the cartridge housing. The cartridge housing may be non-releasably attached to the cartridge, once the cartridge is arranged in the housing, whereby the housing is disposed with the cartridge. In another embodiment the housing is reusable and the cartridge is arranged releasably in the housing.

In a preferred embodiment all the coupling means of the cartridge assembly are unitarily moulded with the cartridge. Thereby, it is possible to construct the cartridge assembly without the housing providing a cartridge assembly with even fewer parts.

The coupling means of the cartridge assembly may be for any suitable coupling, preferably a releasable coupling. Examples of the coupling are snap locks, such as snap locks with guidewire and sideways snap locks, snap locks released through threads, balonet locks, luer locks, hinged locks, threaded locks and any suitable combinations thereof.

The coupling means unitarily moulded with the cartridge are preferably external coupling means, such as an external threaded coupling.

The cartridge may be moulded from any material suitable for medical containers.

The cartridge is preferably moulded from a plastic material, e.g. by injection moulding. A suitable choice of material allows the cartridge to be at least parity transpar-

15:45

HEIDEN & HOTBERG + 43508001

NR. 019

80

5

ent, whereby the user can see whether liquid is left in the cartridge. In a preferred embodiment the cartridge is totally transparent giving the user a greater possibility of inspecting the content of the cartridge.

By using a plastic material as compared to the usual glass material a great advantage is achieved in the production lines. Normally a significant quantity of the produced glass cartridges will be spoiled in the tines due to breakage, however the loss is greatly reduced by the use of plastic cartridges. Furthermore, the risk of small loose glass particles in the cartridges have been eliminated.

10

The cartridge may be of any suitable form, such as a cylinder. The cylinder may be constructed with various combinations of circular or non-circular inner and outer cross-section. In another embodiment the cartridge may be box-shaped having essentially rectangular or triangular cross-section.

15

20

25

30

The stopper is in sliding fluid tight engagement in the cartridge. The stopper is preferably made of plastic and/or rubber material.

The flexibility of the cartridge wall is not critical, however if the cartridge is too flexible the function of the stopper may be impaired. Mostly, the cartridge is made of a material only slightly flexible to non-flexible.

in order to enforce and strengthen the carridge wait the carridge may be integrally moulded with reinforcements. Thereby, the necessity of a projective housing may be obviated. Furthermore, a scale may be integrally moulded with the cartridge wall providing the user with a measure for the medication used and left.

in a most preferred embodiment the cartridge assembly is comprised only of a cattridge being sealed in one end with a sealing, being unitarily plings means and comprising a stopper.

In a cylindrical cartridge the two couplings of the cartridge assembly are generally opposing each other. However, the coupling for engaging with the dosing assembly being separate from coupling for engaging the needle assembly may be arranged in any angle with respect to the latter coupling.

8

15:45

HEIDEN & HOIBERG + 43508201

NR.019

319 99

Another aspect of the present invention is a cartridge being at least parity filled with "figuid medication, such as insulin.

6

In another embodiment the invention relates to a medication delivery device for transferring medication from the cartridge into a syringe with a needle. In this embodiment the coupling means for engaging the needle assembly may be replaced by coupling means for engaging the syringe, or coupling means for both may be provided. The coupling means may be a syringe holder, for example a cylinder coupled to the cartridge comprising a central bore for receiving the syringe. The syringe is coupled to the cartridge having the needle piercing the sealing. By activation of the dosing means the metered amount of medication is driven into the syringe. The syringe is then ready for injection after being removed from the cartridge.

15 Drawings

25

30

35

Fig. 1 is an exploded perspective view of the medication delivery device.

Fig. 2 is a cross-sectional view showing part of the medication delivery device, 2a immediately after assembling before the first injection, and 2b after some time of use.

Fig. 3 is a cross-sectional view showing the cartridge before assembling of the medication delivery device.

Detailed description of the invention

A medication delivery device in accordance with the present invention is identified generally by the numeral 20 in Fig. 1 and 2. Medication delivery device 20 includes a dosing assembly 6, and cartridge assembly 1, a needle assembly 16 and a cap 14.

The dosing assembly 6 is illustrated in Fig. 1 and 2. It is understood, however, that the dosing assembly 6 according to the invention may be any suitable dosing unit including plunger means, and accordingly, that variations from the depicted embodiment may be provided, and are considered to be within the scope of this inven-

17/11/98 15:45 HEIDEN & HOIBERG + 43526201

15

25

30

NR. 019

10

tion. In the depicted embodiment the dosing assembly 6 includes a cylindrical housing surrounding the plunger means 17 of the dosing unit and having opposed proximal and distal ends.

- In one aspect of the Invention the plunger means comprises a rod element 7 which is adapted to engage the stopper 4 of the cartridge assembly 1. The rod element 7 advances axially into the cartridge 5 during Injections. The dosing assembly may have any suitable driving means for advancing the rod element 7.
- 10 The dosing unit 8 preferably also comprises scale means 10 indicating the dosing quantity selected by activating the dose setting means 9 for defining specified selected doses of medication to be delivered. The selected dose may be delivered by actuating the actuator button 16. The actuator button is part of the driving means of the dosing assembly exerting its force on the rod element 7.

The dosing assembly further comprises coupling means 8 adapted for engagement with the cariridge assembly. The coupling means 8 may be internal or external couplings. In a preferred embodiment the coupling 8 is an internal coupling.

20 The cartridge assembly 1 is illustrated in Fig. 1 and 2, and in greater detail in Fig. 3. In Fig. 1 cartridge assembly 1 includes a moulded cartridge 5 extending from proximal end 21 to distal end 22.

At the distal and 22 of the carridge assembly 1 is provided coupling means 2 for releasably mounting a needle assembly 11. At the proximal end 21 of the cartridge assembly 1 is provided coupling means 3 for mounting a dosing assembly 6. The coupling means are as described above.

Cartridge 5 also comprises a stopper 4 in sliding fluid tight engagement within said cartridge 5. The stopper 4 is adapted to receive the plunger means, such as a rod element 7 of the dosing assembly 6. The rod element 7 is adapted to exert an axial movement of the stopper 4 towards the sealed end 22 of the cartridge 5.

17/11/98 15:45 HEIDEN & HOIBERS + 43589891

10

15

20

30

NR. 819

R

The cartridge assembly 1 may further comprise a housing for protecting some or all of the cartridge 5. When the cartridge assembly 1 includes a housing, one of the couplings 2, 3 of the cartridge may be moulded unitarily with the housing.

Instead of the protective housing the cartridge 5 may have integrally moulded reinforcements of the cartridge wall.

The depicted cartridge 5 is cylindrical having couplings 2, 3 at opposed ends. However, the cartridge may obtain any suitable form and the cross-section may be circular or non-circular, such as substantially triangular or oval.

The device according to the invention may include a protective cap 14 that is removably mounted over the cartridge assembly 1 and/or the needle 11 and which is removed before injection of the medication in the cartridge 5. The cap further ensures that the content of the cartridge is protected against suplight.

Referring to Fig. 3 the coupling means of the cartridge are shown in greater detail. The coupling means 3 is an external thread, whereas the coupling means 2 is a recess for a snap lock of the needle assembly. Both coupling means are moulded unitarity with the cartridge.

The various parts of the medication delivery device are advantageously made of plastics, e.g. by injection moulding.

The medication delivery device 20 may further comprise any appropriate needle assembly 11, such as a double ended needle 13 having opposed proximal and distal points and a lumen extending axially therebetween.

A mounting hub 12 is engaged on the needle 13 and is removably connected to the coupling means 2 at the needle end of the cartridge assembly. The relative location of the mounting hub 12 ensures that the proximal point of the needle 13 will pierce the sealing when the mounting hub 12 is engaged with the coupling means 2 on the cartridge assembly 1.

15

17/11/98 15:45 HEIDEN & HOIBERG + 43588881 NR.819 12

9

The needle assembly 11 may further comprise a removable shield or cap 15 for protecting against accidental needle sticks.

The device according to the invention is suitable for delivering pre-set desages of insulin, it is however understood that the device is suitable for the injection of pre-set desages of other liquids.

In use the user will set the dose by means of the dose setting means 9. Before activating the actualor button 18 the cap 14 must be removed from the cartridge assembly 1 whereby the device 20 is prepared for an injection. The injection is effected by activating the actuator button 18, which again will effect the stopper 4 to be moved towards the sealed end 22 of the cartridge 5, thereby delivering the desired pre-set dosage. A subsequent dosage of medication will be set in exactly the same manner as described above. However, for such a subsequent dosage, the rod element 7 and the stopper 4 will be in a partly advanced position as starting point. Dose setting and injections can be carried out until all of the medication has been used.

17/11/98 15:45 HEIDEN & HOIBERG + 43508881 NR.819 1

10

Claims:

5

10

15

30

 A medication delivery device comprising a cartridge assembly, a dosing assembly and optionally a needle assembly.

said cartridge assembly having one end sealed with a pierceable sealing, said end of the cartridge assembly comprising coupling means for engaging a needle assembly, and another end comprising coupling means for engaging the dosing assembly, said cartridge assembly further comprising a cartridge wherein at least one of the coupling means of said cartridge assembly is unitarity moulded with the cartridge, the cartridge further comprising a stopper adapted to receive plunger means, and

- said dosing assembly comprising plunger means having coupling means for engaging the cartridge, and said plunger means is adapted to engage the stopper of the cartridge when the dosing assembly is coupled to the cartridge.
- A medication delivery device according to claim 1, wherein all the coupling means of the cartridge assembly are unitarily moulded with the cartridge.
 - A medication delivery device according to claim 1 or 2, wherein at least one coupling means of the cartridge is an external coupling.
- A medication delivery device according to any of the preceding claims, wherein at least one coupling means of the cartridge is a threaded coupling.
 - A medication delivery device according to any of the preceding claims, wherein the cartridge is moulded of a plastic material.
 - A medication delivery device according to any of the preceding claims, wherein
 the cartridge is at least parity transparent.
- A medication delivery device according to any of the preceding claims, wherein
 reinforcements of the cartridge wall are integrally moulded with the cartridge.

17/11/98 15:45

10

30

HEIDEN & HOIBERG + 43509001

NR.019

11


- 8. A medication delivery device according to any of the preceding claims, wherein the cartridge further comprises a cartridge housing.
- 9. A medication delivery device according to any of the preceding claims, wherein the cartridge further comprise a scale.
 - 10. A medication delivery device according to any of the preceding cialins, wherein the cross-section of the cartridge is non-circular.
 - 11. A medication delivery device according to any of the preceding dalms, wherein the coupling means of the cartridge are opposed each other.
- 12. A cartridge assembly for use in a medication delivery device, said ¢artridge assembly having one end sealed with a pierceable sealing, said end of the car-. 15 tridge assembly comprising coupling means for engaging a needle assembly, and another end comprising coupling means for engaging the dosing assembly. said cartridge assembly further comprising a cartridge wherein at least one of the coupling means of said cartridge assembly is unitarily moulded with the car-20 tridge, said cartridge further comprising a stopper.
 - 13. A cartridge assembly according to claim 12, wherein all the coupling means of the cartridge are unitarily moulded with the cartridge.
 - 14. A cartridge assembly according to daim 12 or 13, wherein at least one coupling 25 means of the cartridge is an external coupling.
 - 15. A cartridge assembly according to any of the claims 12-14, wherein at least one coupling means of the cartridge is a threaded coupling.
 - 16. A cartridge assembly according to any of the claims 12-15, wherein the cartridge is moulded of a plastic material.
 - 17. A cartridge assembly according to any of the preceding 12-16, wherein the car-35 tridge is at least partly transparent.


15

17/11/98 HEIDEN & HITTERE > 43500001 NR.019 15

12

- 18. A cartridge assembly according to any of the claims 12-17, wherein reinforcements of the cartridge wall are integrally moulded with the cartridge.
- 19. A cartridge assembly according to any of the claims 12-18, wherein the cartridge further comprises a cartridge housing.
 - 20. A cartridge assembly according to any of the claims 12-19, wherein the cartridge further comprise a scale.
 - 21. A cartridge assembly according to any of the claims 12-20, wherein the crosssection of the cartridge is non-circular.
 - 22. A carridge assembly according to any of the claims 12-21, wherein the coupling means of the cartridge are opposed each other.
 - 23. A cartridge assembly according to any of the claims 12/22, which is filled with medicine.





						1		
614×								
0	<i>-</i>	:			<i>p</i>	ŀ		8.1
(1)		1			(
DEC 1 8 2907	•	PART B - F	EE(S) TRANSI	ATTTAL				
			fal en Mar Da	- icciie, ki	PF.		•	4
Complete and send th	in torm, together with	subfrespie resi	(s), to: man bo	mmisioner E 1930 E E 1	r for Patents			7
PADENTI			W	chington, I	D.C. 20231			1
			Fax (79	3)746-4900				63/
NSTRUCTIONS: The form	should be used for transmit	ting the ISSUE FE	E and PUBLICATI	ON FEE (if n	equired). Blocks ! or will be mailed !	drough 4 should a the current corr	oc completed w	here /
NSTRUCTIONS: This form propriete. All further corresponds to the	or directed otherwise is i	Block I, by (s) spec	cifying a new control	poedesco edile	ant and/or (b) and	scating a separate	LEE YDDKE22	for
	DUREN (Fee: Lags); makes; with		<u> </u>	Ar: A contribut	e of making cap o	nly be used for doc	cele mailings of	5
2613T 7590	99/20/2002		Fo.	c(s) Trensmit connectving p	ist. This contino good. Each additi	nly be used for don size extract be to coal paper, such a scrificate of mailing	e est expressionscrip est tot fest og	ot.
PATENT DEPART	MENT MAYC	A. Isega	n,tsg. w	mal drawing, r	ment perso its own o	entificate of mailing	or temperaturion.	
SKADDEN, ARPS, S	LATE MEAGHER &	EIOMILE	.		Certificate of Mai	ing or Treasmiss	#4 	•-
FOUR TIMES SQUA	THE NEW NOOD	lick that	cals, is	ited States Pos	tel Sciance Auth an	ficient postage for	first clear muli in	100
WEN LOW'N LA	DA.	14.+	Inc.	recipient to the	USPTO, on the de	te indicated below,	c, or occur means	<u></u>
100 t	college how	a over		Rock	ida He	Jii	(Department)	
0	+ 015	08540		Die	- ii	ij.	(Signe	_
Nince	College Roa ton, NJ	•	 -	Dece	July 12	2002		ज
	a			<u> </u>				
APPLICATION NO.	FELDIO DATE	FDSI	KYNOD BALEALOR		ATTOENEY		NETRIKATION NO	لن
09/348,536	07/07/1999		S BUCH RASMUSS	EN	5637.20	o us	5366	
TILE OF INVENTION: MED	ICATION DELIVERY DEV	TICE	•		•			
						1 *		
						1 .		
	BHALL BRITUY	ISSUE FEE	MUBLICAS	ION FEE	TOTAL FEED	n asura	DATE DUE	7
ARPLN, TYPE	NO NO	\$1280	1 (00000		\$1280		12/20/2002	
pogrevitional		31400	•	,		`	12202002	
EXAMPLE		ART UNIT	CLASSERGASE		•	·		
STRMONS, KE		3763	604-232000					
						 		•
i. Change of correspondence of R 1363).	eddras or indication of "For a	Address* (37	2. For printing on the numer of up to	he petent trod I residered o	e pago, max (1) . strai acomeys .	Marc A	- Began,	Esal
								- • • •
	a whiteness (our Charmes of Court	annoisses I	or agency OR, since	matively, (2) (the monet of a	I		
Address form PTO/SE/122)	e address (or Change of Court attached		single firm (bering	macively, (2) (; as a somebo	the mone of a ranginered	I	W. Box	
Address form PTO/SS/122)	generation. (or "live Address" indication :	6-m	single firs (sering streamy or sprof) sugarand point st	matively, (2) (; as a monde and the trans amoys or ages	the memor of a er a registered es of up to 2	Richard	W. Box	
Address form PTO/SS/122)	Resident	6-m	single firm (sering attendey or agent)	matively, (2) (; as a monde and the trans amoys or ages	the memor of a er a registered es of up to 2	Richard		
O "For Address" indication PTO/SB/47; Ray 03-02 or o Number is required.	(or "Fee Address" Indication to the state of	form A Customer RINTED ON THE P	single firm (sering attention or agent) registered patent att is listed, no instant w PATENT (print or ty)	matively, (2) () as a mondate and the mean tenors or agen If he printed.	the name of a er a regimentel es of up to 2 as, if so sume	Richard Reza G	N. Book	Ecq Sq-
O "For Address" indication PTO/SB/47; Ray 03-02 or o Number is required.	(or "Fee Address" Indication to the state of	form A Customer RINTED ON THE P	single firm (sering attention or agent) registered patent att is listed, no instant w PATENT (print or ty)	matively, (2) () as a mondate and the mean tenors or agen If he printed.	the name of a er a regimentel es of up to 2 as, if so sume	Richard Reza G	N. Book	Ecq Sq-
Address form FTV/SB/122) O Teo Address fundation PTU/SB/47; Rev 03-12 or or Number is required. ASSIGNEE NAME AND RI FLEASE NOTE: Unless on a been previously submitted to	(or "Fee Address" Indication to the state of	form a Customer RINTED ON THE F so assigness data will not under separate o	single first (saving attendey or agent) registered petrot at is listed, no remo w PATENT (print or ty I appear on the pater course, Camplesion of	matively, (2) () as a morabe end the mean move or agen if be printed. **) 2. In this on the day form is 14	the name of a set a registrored as of up to 2 as . If so some	Richard Reza G	N. Book	Ecq Sq-
Address form FTUNENTED OFFO Address 'entrement FTUNENTE, Earl GP-GO or e Number is required. ASSIGNEE NAME AND RI FLEASE NOTE: Unless on e been previously asternized in (A) NAME OF ASSIGNEE	gracional description (ar "For Address" Indication on the recent) etherhold. Use of a second second of the second second of the second of the second of the USPTO or is being estumistic to the USPTO or is being estumistic	EINTED ON THE F or arriginal data will med under separate of (B) RES	single firm (moving attention or agency registered potent at its listed, no name w PATENT (prior or tr) I uppose on the part over. Completion of https://ex.	matively, (2) () as a morabe end the mean move or agen if be printed. **) 2. In this on the day form is 14	the name of a set a registrored as of up to 2 as . If so some	Richard Reza G	N. Book	Ecq Sq-
Address form FTUNENTED OFFO Address 'entrement FTUNENTE, Earl GP-GO or e Number is required. ASSIGNEE NAME AND RI FLEASE NOTE: Unless on e been previously asternized in (A) NAME OF ASSIGNEE	gracional description (ar "For Address" Indication on the recent) etherhold. Use of a second second of the second second of the second of the second of the USPTO or is being estumistic to the USPTO or is being estumistic	EINTED ON THE F or arriginal data will med under separate of (B) RES	single first (saving attendey or agent) registered petrot at is listed, no remo w PATENT (print or ty I appear on the pater course, Camplesion of	matively, (2) () as a morabe end the mean move or agen if be printed. **) 2. In this on the day form is 14	the name of a set a registrored as of up to 2 as . If so some	Richard Reza G	N. Book	Ecq Sq-
Address form PTO-SEVEZ. O "For Address" infraction PTO-SEVEZ; Rew 63-92 or or Number is required. ASSIGNEE NAME AND RI FLEASE NOTE: Unless on temp previously extended to: (A) NAME OF ASSIGNEE NOVe Note:	Ger Foe Address' indication from recently established. Use of established the offer statement of the stateme	form a Casterner RECTED ON THE F or satisface data with the under separate (B) RES	single firm (baring attention of settler agent) regard settler at its listed, no seems w PATENT (print or typ I appear on the paint over. Completion of siDENCE (CITY so g S V A U.S. A	matively, (2) (g. w. w. stoomber and the treat comeys or agen if the printed at fact the come is at fact to the come is at fact to the come is at fact to the come is at fact to the come is at fact to the come is at fact to the come is at fact to the come is at fact to the come is at fact to the come is at fact to the come is at fact to the come is at fact to the come is at fact to the come is at fact to the come is at fact to the come is at fact to the c	the memor of a r a registered of a r a registered or a r a registered or a r a r a r a r a r a r a r a r a r	Rechard Reza G	W. Box	Erg Fry-
Address form PTO-SEM 22. O "For Address" infraction PTO-SEM 27, Rew 63-92 or or Number is required. ASSIGNEE NAME AND RI FLEASE NOTE: Unless on tem previously extended in (A) NAME OF ASSIGNEE NOVO NOTE Sexue check the appropriate as	Ger Foe Address' indication on more property indication. The extended the extended the extended below, a the USFTO or is being attended below. In the USFTO or is being attended below. The USFTO or is being attended below.	form a Casterner RECTED ON THE F or satisface data with the under separate (B) RES (will not be printed	single firm (series strongs) or signal) segment or signal) segment of the series of th	matively, (2) (g. w. w. stoomber and the treat comeys or agen if the printed at fact the come is at fact to the come is at fact to the come is at fact to the come is at fact to the come is at fact to the come is at fact to the come is at fact to the come is at fact to the come is at fact to the come is at fact to the come is at fact to the come is at fact to the come is at fact to the come is at fact to the come is at fact to the come is at fact to the c	the memor of a r a registered of a r a registered or a r a registered or a r a r a r a r a r a r a r a r a r	Richard Reza G	W. Box	Erg Fry-
Address form FTUNSDIZE) O TEO Advisors' infraction DTUSSE47: Raw GL-GC or a Number is required. ASSIGNEE NAME AND RI FLEASE NOTE: Unless on a been previously administed in 1 (A) NAME OF ASSIGNEE NOVO NOTE Tense check the appropriate as is. The following foo(s) are easier.	Ger Foe Address' indication on more property indication. The extended the extended the extended below, a the USFTO or is being attended below. In the USFTO or is being attended below. The USFTO or is being attended below.	RINTED ON THE F to strigger data will not under separate (8) RES (will not be printed.	single firm (swring strongs) or signal) sugintarial patent at it is listed, no summe w PATENT (print or try I appear on the parameter of the patent) and the patent) are the patent)	matively, (2) (matively, (2)	the insure of a registered re a registered as of up to 2 cas. If no sumo of the registered data is no OT a substitute for COUNTRY)	Rechard Reza G	W. Box	Erg Fry-
Address form FTUNSDIZE) O TEO Advinces indication PTUNSDIAT: Bor GL-GC or a Namber is required. ASSIGNEE NAME AND RI FLEASE NOTE: Unless an a been previously submitted to ! (A) NAME OF ASSIGNEE NOVO NOTE Tease check the appropriate as a. The following fie(i) are con [6] issue For	Ger Foe Address' indication on more property indication. The extended the extended the extended below, a the USFTO or is being attended below. In the USFTO or is being attended below. The USFTO or is being attended below.	RENTED ON THE F so assigner data will not under separate o (8) RES (4) Il not be printed. 4) Pays Q A che	single firm (series strongs or signs) represented potent at its listed, so passes with ATENT (print or try). I appear on the passes over. Completion of strike N.C. (CTTY on the passes) on the passes, the passes of the passes of the passes, the passes of the passes, the passes of the passes, the passes of the passes of the passes, the passes of the pa	matively, (2) of the season of the mean or season of season of the printed. **) ** ** ** ** ** ** ** **	the insure of a registered re a registered re cognitive of up to 2 case. If no name of the cognitive of the	Rechard Reza G	W. Box	Erg Fry-
Address form FTUNSHIZE) O TEO Address indication. PTUNSHIP, Row (II-QU or a reasonable is required. ASSIGNEE NAME AND RIFE FLEASE NOTE: Unless on a been previously exhausted to (A) NAME OF ASSIGNEE NOVO NOTE (Manas check the appropriate as a Teo following foo(s) are configured to the same of the configured foo(s) are configured foo(s) are configured foo(s).	(or "Foe Address" indication for record) etached. Use of a particular record) etached. Use of a particular record) etached. Use of a particular record in indication in in	form a Customer RENTED ON THE F to attigues data will not under separate o (B) RES B 4. (will not be printed Q A clos Q Psym	single firm (suring strongs or signs), suggestioned patent at its listed, so pame with the patent of	matively, (2) of the said the means of the means of the means of the period. 2. Inclusion of this form is No. 1 STATE OR (C. 1) of the means of the means of the means of the form is No. 1 STATE OR (C. 1) of the means of the m	the insure of a transparent of a transparent of the to 2 case. If no summe of a substantial for COUNTRY) A corporation or or colored, is attached.	Rechard Reza C Composition who compos	M. Bo of	Erq
Address form FTUNSHIZE) O TEO Address indication PTUNSHIP: Row GL-QC or a PERMISHER IN THE WALLE AND RI PLEASE NOTE: Unless sea a been previously submitted to ! (A) NAME OF ASSIGNEE NOVO NOTE Texas check the appropriate as a. The following fie(i) are cas (5) issue For	(or "Foe Address" indication for record) etached. Use of a particular record) etached. Use of a particular record) etached. Use of a particular record in indication in in	form a Customer RENTED ON THE F to attigues data will not under separate o (B) RES B 4. (will not be printed Q A clos Q Psym	single firm (series strongs or signs) represented potent at its listed, so passes with ATENT (print or try). I appear on the passes over. Completion of strike N.C. (CTTY on the passes) on the passes, the passes of the passes of the passes, the passes of the passes, the passes of the passes, the passes of the passes of the passes, the passes of the pa	matively, (2) of the said the means of the means of the means of the period. 2. Inclusion of this form is No. 1 STATE OR (C. 1) of the means of the means of the means of the form is No. 1 STATE OR (C. 1) of the means of the m	the insure of a transparent of a transparent of the to 2 case. If no summe of a substantial for COUNTRY) A corporation or or colored, is attached.	Rechard Reza C Composition who compos	M. Bo of	Erq
Address form FTUNSHIZE) O TEO Address indication PTUNSHIP; Bare (II-QU or a reasonable is required. ASSIGNEE NAME AND RI FLEASE NOTE: Unless on a been previously exhausted to learn state of the previously exhausted to learn should be a second to lear	(or "Foe Address" indication for record) etached. Use of a particular record) etached. Use of a particular record) etached. Use of a particular record of the desired below, a fee USPTO or is being extend that ALS sugmes exceptory or composter absent:	RINTED ON THE F to strigger data will not under separate (B) RES (will not be printed 40. Payr C A che C Payr More and C Payr C The C	single firm (series strongs or signs) segment of season with the listed, so present with the listed, so present with the listed, so present with the listed of the listed	matricy, (2) (matricy, (2) (matricy, (2) (matricy, (2) (matrice) matrice of special (the insure of a registered re a registered in a structured.	Richard Reza G composition who composition private group cod foo(s), or crofits apply of this form)	M. Bo of	Ese
Address form FTUNSHIZE) O TEO Address indication PTUNSHIP; Bare (II-QU or a reasonable is required. ASSIGNEE NAME AND RI FLEASE NOTE: Unless on a been previously exhausted to learn state of the previously exhausted to learn should be a second to lear	(or "Foe Address" indication for record) etached. Use of a particular record) etached. Use of a particular record) etached. Use of a particular record of the desired below, a fee USPTO or is being extend that ALS sugmes exceptory or composter absent:	RINTED ON THE F to strigger data will not under separate (B) RES (will not be printed 40. Payr C A che C Payr More and C Payr C The C	single firm (series strongs or signs) segment of season with the listed, so present with the listed, so present with the listed, so present with the listed of the listed	matricy, (2) (matricy, (2) (matricy, (2) (matricy, (2) (matrice) matrice of special (the insure of a registered re a registered in a structured.	Richard Reza G composition who composition private group cod foo(s), or crofits apply of this form)	M. Bo of	Ese
Address from FTUNSHILL) O TEO Address indication. PTUNSHIP; Roy (U-Q2 or a reasonable is required. ASSIGNIE NAME AND RIPERASE NOTE: Unless on a been previously exhausted to learn prev	(or "Fee Address" indication for record) effected. Use of a personal part of the of a personal part of the of a personal part of the office of	RINTED ON THE F to strigger data will not under separate (#10 not be printed 4. Pays Q. A che Q. Pays ACT Deposit and Publication For	single firm (series strongs or signs) segment of season with the listed, so present with the listed, so present with the listed, so present with the listed of the listed	matricy, (2) (matricy, (2) (matricy, (2) (matricy, (2) (matrice) matrice of special (the insure of a registered re a registered in a structured.	Richard Reza G composition who composition private group cod foo(s), or crofits apply of this form)	M. Bo of	Erq
Address from FTUNSHILL) O TEO Address indication. PTUNSHIP; Roy (U-Q2 or a reasonable is required. ASSIGNEE NAME AND RIPERASE NOTE: Unless on a been previously extended to leave provided the province of the leave for leave for the province of the leave for leave for leave for leave for leave for leave for leave is not leave for leave for leave in the leave for leave for leave is not leave for leave for leave in the leave for leave for leave in the leave for leave for leave for leave for leave in the leave for leave	(or "Foe Address" indication for record) etached. Use of a particular record) etached. Use of a particular record) etached. Use of a particular record of the desired below, a fee USPTO or is being extend that ALS sugmes exceptory or composter absent:	RECTED ON THE F as arrigant data will not under separate (#10 not be priozed 40. Pays Q A che Q Pays (#10 not be priozed 40. Pays (#	single firm (suring strongs or signs) registered potent at its listed, so some we represent our control of the part of the par	matricy, (2) (matricy, (2) (matricy, (2) (matricy, (2) (matrice) matrice of special (the insure of a registered re a registered in a structured.	Richard Reza G composition who composition private group cod foo(s), or crofits apply of this form)	M. Bo of	Erq
Address form FTUNSHIZE) O TEO Address indication PTUNSHIZE, Bow GLAZ or a Nearthful Service of ASSIGNEE NAME AND RIFERASE NOTE: Unless on a been previously submitted to (A) NAME OF ASSIGNEE NOVO NOTE Issue check the appropriate as a Teo following fac(s) art cas Mi issue Foc M Publication Foc SAdvance Order - # of Copi Commissioner for Pearsts is recommissioner for Pearsts is recommissioner for Pearsts in recommissioner Signature) Australian Signature) Australian Signature) AMM A MM	(or "Foe Address" indication has record) etached. Use of a PSIDENCE DATA TO BE FI indignoe is indicatified below, a the USFTO or is being admit that A A Suppose caregory or componies almost: 1. A A Suppose Caregory or componies almost:	form a Customer RINTED ON THE F as assigner data will not under separate (B) RES (will not be printed Q. Peyr Q. A che Q. Peyr Ä. The C Deposit and Publication For	single firm (series statement or segme) segment or segme) segment of the series of the	matricy, (2) (; se a monthly control of spend control of	the insure of a range of the range of the section o	Rechard Reza G ch appropriate who filling an entipercent that private group that private group one foo(s), or crofin copy of this form o be application to	M. Bo of Secretary Comments of Secretary Com	Erq
Address form FTUNSHIZE) O TEO Address indication PTUNSHIZE, Bow GLAZ or a Nearthful Service of ASSIGNEE NAME AND RIFERASE NOTE: Unless on a been previously submitted to (A) NAME OF ASSIGNEE NOVO NOTE Issue check the appropriate as a Teo following fac(s) art cas Mi issue Foc M Publication Foc SAdvance Order - # of Copi Commissioner for Pearsts is recommissioner for Pearsts is recommissioner for Pearsts in recommissioner Signature) Australian Signature) Australian Signature) AMM A MM	(or "Foe Address" indication has record) etached. Use of a PSIDENCE DATA TO BE FI indignoe is indicatified below, a the USFTO or is being admit that A A Suppose caregory or componies almost: 1. A A Suppose Caregory or componies almost:	form a Customer RINTED ON THE F as assigner data will not under separate (B) RES (will not be printed Q. Peyr Q. A che Q. Peyr Ä. The C Deposit and Publication For	single firm (series statement or segme) segment or segme) segment of the series of the	matricy, (2) (; se a monthly control of spend control of	the insure of a registered re a registered in a structured.	Rechard Reza G ch appropriate who filling an entipercent that private group that private group one foo(s), or crofin copy of this form o be application to	M. Bo of	Erq
Address form FTUNSHIZE) O TEO Address indication PTUNSHIZE, Bow GLACE or a reasonable is respected. ASSIGNEE NAME AND RIFERAND RIFERASE NOTE: Unless on a tem previously submitted to (A) NAME OF ASSIGNEE NOVO NOTE Issue check the appropriate as a Teo following fre(s) are con in issue For RIFERASE Order - 8 of Copi Commissioner for Pennis is recommissioner for Pennis is recommended. Australiand Signature) NOTE: The Issue For said NOTE. NOTE: The Issue For said Signature of the Pennis is recommended.	(or "Foe Address" indication for record) etached. Use of a particular to BE FI section of the USPTO or is being admit to the	form a Customer RINTED ON THE F as assigned data will not under separate of (B) RES (will not be printed QA che QA Payr QA che (Deposit The C (Cute) 12/12/ will not be accepte of the samples of	single firm (series strong) or agent) suginized patent at its listed, no neme w PATENT (print or tyll oppose on the passe over. Completion of sillen (CITY on the passet) over of Fools; continued to the series o	matricy, (2) (; as a something control of special c	de insue of a rangement of a rangement of any to 2 case. If no sumo of a publishment is a configurate data in a OT a publishment for COUNTRY) A exponention or of the country of the configurate of a country of the co	Rechard Reza C The appropriate who filling an assignment that private group that private group that private group the spring of this form t	M. Bo of Secretary Comments of Secretary Com	Erq
Address form FTONSHILL) O TEO Address indication D TEO Address indication PERSON TO THE STATE OF THE STATE	(or "Foe Address" indication for record) etached. Use of a particular to BE FI section of the USPTO or is being admit to the	form a Customer RINTED ON THE F as assigned data will not under separate (B) RES (will not be printed QA che QA pay QA che (Deposit The C (Cutt) (2/12/ Will not be accepte of the samples of the samples of	single firm (series strong) or agent) suginized patent at its listed, no neme w PATENT (print or tyll oppose on the passe over. Completion of sillen (CITY on the passet) over of Fools; continued to the series o	matricy, (2) (; ms a member of the matrix of the member of the form in Nt is STATE ON C O individual the fact of the form in Nt is STATE ON C O individual the fact of the member of the	the insure of a registrated as of up to 2 and to 10 and 10	Rechard Company of the appropriate who they private group of the form of the appropriate Market Private group of the form of the appropriate Market Private group of the form of the appropriate Market Private Group of the appropriate Market Privat	M. Bo of Secretary Comments of Secretary Com	Erq
Address form FTONSHILL) O TEO Address indication D TEO Address indication PERSON TO THE STATE OF THE STATE	(or "Foe Address" indication for record) etached. Use of a particular to BE FI section of the USPTO or is being admit to the	form a Customer RINTED ON THE F as assigned data will not under separate (B) RES (will not be printed QA che QA pay QA che (Deposit The C (Cutt) (2/12/ Will not be accepte of the samples of the samples of	single firm (series strong) or agent) suginized patent at its listed, no neme w PATENT (print or tyll oppose on the passe over. Completion of sillen (CITY on the passet) over of Fools; continued to the series o	matricy, (2) (; as a something control of special c	the insure of a registrated as of up to 2 and up to 2	Rechard Company of the appropriate who they private group of the form of the appropriate Market Private group of the form of the appropriate Market Private group of the form of the appropriate Market Private Group of the appropriate Market Privat	M. Bo of Secretary Comments of Secretary Com	Erq
Address form FTONSHILL) O TEO Address indication D TEO Address indication PERSON TO THE STATE OF THE STATE	(or "Foe Address" indication for record) etached. Use of a particular to BE FI section of the USPTO or is being admit to the	form a Customer RINTED ON THE F as assigned data will not under separate (B) RES (will not be printed QA che QA pay QA che (Deposit The C (Cutt) (2/12/ Will not be accepte of the samples of the samples of	single firm (series strong) or agent) suginized patent at its listed, no neme w PATENT (print or tyll oppose on the passe over. Completion of sillen (CITY on the passet) over of Fools; continued to the series o	matricy, (2) (; ms a member of the matrix of the member of the form in Nt is STATE ON C O individual the fact of the form in Nt is STATE ON C O individual the fact of the member of the	the insure of a registrated as of up to 2 and to 10 and 10	Rechard Company of the appropriate who they private group of the form of the appropriate Market Private group of the form of the appropriate Market Private group of the form of the appropriate Market Private Group of the appropriate Market Privat	M. Bo of Secretary Comments of Secretary Com	Erq
Address form FTONSHILL) O TEO Address indication D TEO Address indication PERSON TO THE STATE OF THE STATE	(or "Foe Address" indication have recomb) estacked. Use of a PSIDENCE DATA TO BE FI seignore is independed before, a the USFTO or is being administrative of the Companion of the USFTO or is being administrative of the USFTO or is being administrative or componion in the USFTO or is being administrative or componion in the USFTO or is being administrative or componion.	form a Customer RINTED ON THE F as assigned data will not under separate (B) RES (will not be printed QA che QA pay QA che (Deposit The C (Cutt) (2/12/ Will not be accepte of the samples of the samples of	single firm (series strong) or agent) suginized patent at its listed, no neme w PATENT (print or tyll oppose on the passe over. Completion of sillen (CITY on the passet) over of Fools; continued to the series o	matricy, (2) (; ms a member of the matrix of the member of the form in Nt is STATE ON C O individual the fact of the form in Nt is STATE ON C O individual the fact of the member of the	the insure of a registrated as of up to 2 and to 10 and 10	Rechard Company of the appropriate who they private group of the form of the appropriate Market Private group of the form of the appropriate Market Private group of the form of the appropriate Market Private Group of the appropriate Market Privat	M. Bo of Secretary Comments of Secretary Com	Erq
Address form FTONSHILL) O TEO Address indication D TEO Address indication PERSON TO THE STATE OF THE STATE	(or "Foe Address" indication have recomb) estacked. Use of a PSIDENCE DATA TO BE FI seignore is independed before, a the USFTO or is being administrative of the Companion of the USFTO or is being administrative of the USFTO or is being administrative or componion in the USFTO or is being administrative or componion in the USFTO or is being administrative or componion.	form a Customer RINTED ON THE F as assigned data will not under separate (B) RES (will not be printed QA che QA pay QA che (Deposit The C (Cutt) (2/12/ Will not be accepte of the samples of the samples of	single firm (series strong) or agent) suginized patent at its listed, no neme w PATENT (print or tyll oppose on the passe over. Completion of sillen (CITY on the passet) over of Fools; continued to the series o	matricy, (2) (; ms a member of the matrix of the member of the form in Nt is STATE ON C O individual the fact of the form in Nt is STATE ON C O individual the fact of the member of the	the insure of a registrated as of up to 2 and to 10 and 10	Rechard Company of the appropriate who they private group of the form of the appropriate Market Private group of the form of the appropriate Market Private group of the form of the appropriate Market Private Group of the appropriate Market Privat	M. Bo of Secretary Comments of Secretary Com	Erq
Address form FTO'S 18 12) O TEO Advices indication. D TEO Advices indication. PERSONAL P. Rev (U-OL or a reasonable is required. ASSIGNEE NAME AND RIP. PEASE NOTIE: Unless on a been previously exhemited to learn proviously exhemited to following free(s) are careful for the later for Penerts is recommended to learn proviously exhemited to learn proviously exhemited to learn a benefit by explanation or remain a benefit by explanation of the late of	(or "Fee Address" indication for record) etached Use of a second stacked use of the Usero or component stacked to septy of a second stacked use of the United States Feeting of the Usero of the Usero of States I second to Stat	form a Cestemer a Cestemer a Cestemer b Control of THE F as arrigant data with the under separate (B) RES Gall not be printed 4. Pays Q A che Q Pays (STE CO Obposit 12/12/ 12/2/ 13/12/ 13/12/ 13/12/ 14 De unformation of the satispace or and I reduced Off 11 De unformation of TCPR 1.14. The unit property of the deprinted of the satispace or and I reduced Off 11 De unformation of TCPR 1.14. The unit property of the chief informatic the Chief information THES ADDRESS	single firm (swring strengs or signs) registered patent at its listed, so some we harriers (point or type) of special strengs or construction of sure of Foo(s). ATENT (print or type) of special strengs on the patent) of the sure of Foo(s) or to see any other party in the sure of th	matricy, (2) (; ms a member of the matrix of the member of the form in Nt is STATE ON C O individual the fact of the form in Nt is STATE ON C O individual the fact of the member of the	the insure of a registrated as of up to 2 and to 10 and 10	Rechard Company of the appropriate who they private group of the form of the appropriate Market Private group of the form of the appropriate Market Private group of the form of the appropriate Market Private Group of the appropriate Market Privat	M. Bo of Secretary Comments of Secretary Com	Erq
Address form FTO'S 18 12) O TEO Advices indication. D TEO Advices indication. PERSONAL P. Rev (U-OL or a reasonable is required. ASSIGNEE NAME AND RIP. PEASE NOTIE: Unless on a been previously exhemited to learn proviously exhemited to following free(s) are careful for the later for Penerts is recommended to learn proviously exhemited to learn proviously exhemited to learn a benefit by explanation or remain a benefit by explanation of the late of	(or "Fee Address" indication for record) etached Use of a second stacked use of the Usero or component stacked to septy of a second stacked use of the United States Feeting of the Usero of the Usero of States I second to Stat	form a Cestemer a Cestemer a Cestemer b Control of THE F as arrigant data with the under separate (B) RES Gall not be printed 4. Pays Q A che Q Pays (STE CO Obposit 12/12/ 12/2/ 13/12/ 13/12/ 13/12/ 14 De unformation of the satispace or and I reduced Off 11 De unformation of TCPR 1.14. The unit property of the deprinted of the satispace or and I reduced Off 11 De unformation of TCPR 1.14. The unit property of the chief informatic the Chief information THES ADDRESS	single firm (swring strengs or signs) registered patent at its listed, so some we harriers (point or type) of special strengs or construction of sure of Foo(s). ATENT (print or type) of special strengs on the patent) of the sure of Foo(s) or to see any other party in the sure of th	matricy, (2) (; ms a member of the matrix of the member of the form in Nt is STATE ON C O individual the fact of the form in Nt is STATE ON C O individual the fact of the member of the	the insure of a registrated as of up to 2 and to 10 and 10	Rechard Company of the appropriate who they private group of the form of the appropriate Market Private group of the form of the appropriate Market Private group of the form of the appropriate Market Private Group of the appropriate Market Privat	M. Bo of Secretary Comments of Secretary Com	Erq
Address form FTONSHILL) O TEO Address indication D TEO Address indication PERSON TO THE STATE OF THE STATE	(or "Fee Address" indication for record) etached Use of a second stacked use of the Usero or component stacked to septy of a second stacked use of the United States Feeting of the Usero of the Usero of States I second to Stat	form A Customer A Customer A Customer A Customer A Customer B Down Compared Co	single firm (surface strongs or signs) sugarized patent at its listed, no name we harried patent at its listed, no name we harried (point or ty) I appear on the patent or ty	in a manufacture of the form in Nr. 15 TATE ON 15 T	the inner of a registrated as of up to 2 and up to 2 a	Rechard Company of the private group of the form of the company of the comp	M. Bo of Arear, E. Arear, E. Arear, C. Government,	Erq
Address from FTUNSDIA2) O TEO Advisors' indication D TEO Advisors' indication PERSON TO THE CONTROL OF EXPENDIANT IS TO THE CONTROL OF EXPENDIANT IN THE CONTROL OF EXECUTED IN THE CONTROL OF THE CON	(or "Foe Address" indication for record) etached Use of a part record) etached Use of a part record) etached Use of a part record of the control of the USPTO or is being admit the use of the USPTO or is being admit the USPTO. The part of the United Subsection for (if recorded by 35 USPS Funds to the USPTO. These will vie to the USPTO. The wall vie to the wall vie to the USPTO. The wall vie to the USPTO. The wall vie to	form a Customer a Cust	single firm (series strongs or signs) registered potent at it is listed, so some with the potent of	in a manufacture of the form in Nr. 15 TATE ON 15 T	the inner of a registrated as of up to 2 and up to 2 a	Rechard Company of the appropriate who they private group of the form of the appropriate Market Private group of the form of the appropriate Market Private group of the form of the appropriate Market Private Group of the appropriate Market Privat	M. Bo of Arear, E. Arear, E. Arear, C. Government,	Erq
Address form FTONSHILD. O FEO Address' indication. D FEO Address' indication. FTONSHAT: Roy (UQ. or a Neurober to required. ASSIGNEE NAME AND RIP FTONSHILD. ASSIGNEE NOTIFE: Unless on a been previously submitted to (A) NAME OF ASSIGNEE NOVO NOTIFICATION TO ASSIGNEE NOVO NOTIFICATION TO ASSIGNEE NOVO NOTIFICATION TO ASSIGNEE A The following foo(s) are can be following foo(s) are can be following foo(s) are can be followed by the control of the proposed to the can be considered by the control of the can be considered to the control of the can be considered to the can be benefit by explication. Confidentially in secure to the considered to the can be benefit by explication. Confidentially in secure to the considered to the can be benefit by explication. Confidentially in secure to the considered to the can be benefit by explication. Confidentially in the completed special control of the can be benefit by explication of the can be benefit by the can be benefit by explication of the can be benefit by the benefit by the can be benefit by the b	(or "Foe Address" indication for record) etached Use of a part record) etached Use of a part record) etached Use of a part record of the control of the USPTO or is being admit the use of the USPTO or is being admit the USPTO. The part of the United Subsection for (if recorded by 35 USPS Funds to the USPTO. These will vie to the USPTO. The wall vie to the wall vie to the USPTO. The wall vie to the USPTO. The wall vie to	form a Customer a Cust	single firm (series strongs or signs) registered potent at it is listed, so some with the potent of	in a manufacture of the form in Nr. 15 TATE ON 15 T	the inner of a registrated as of up to 2 and up to 2 a	Rechard Le ZA C C C appropriate who there private group there private group to be application to copy of this form 0 to application to CE ARTMENT OF	M. Bo of Areas.	Erg
Address from FTONSH 12). O From Advices indication. D From Advices indication provided and pro	(or "Foe Address" indication for record) etached Use of a part record) etached Use of a part record) etached Use of a part record of the control of the USPTO or is being admit the use of the USPTO or is being admit the USPTO. The part of the United Subsection for (if recorded by 35 USPS Funds to the USPTO. These will vie to the USPTO. The wall vie to the wall vie to the USPTO. The wall vie to the USPTO. The wall vie to	form a Customer a Cust	single firm (series strongs or signs) registered potent at it is listed, so some with the potent of	in a manufacture of the form in Nr. 15 TATE ON 15 T	the inner of a registrated as of up to 2 and up to 2 a	Rechard Company of the private group of the form of the company of the comp	M. Bo of Areas.	Erg
Address from FTONSH 12). O From Advices indication. D From Advices indication provided and pro	(or "Foe Address" indication for record) etached Use of a part record) etached Use of a part record) etached Use of a part record of the control of the USPTO or is being admit the use of the USPTO or is being admit the USPTO. The part of the United Subsection for (if recorded by 35 USPS Funds to the USPTO. These will vie to the USPTO. The wall vie to the wall vie to the USPTO. The wall vie to the USPTO. The wall vie to	form a Customer a Cust	single firm (series strongs or signs) registered potent at it is listed, so some with the potent of	in a manufacture of the form in Nr. 15 TATE ON 15 T	the inner of a registrated as of up to 2 and up to 2 a	Rechard Le ZA C C C appropriate who there private group there private group to be application to copy of this form 0 to application to CE ARTMENT OF	M. Bo of Areas.	Erg
Address from FTUNSDIA2) O TEO Advisors' indication D TEO Advisors' indication PERSON TO THE CONTROL OF EXPENDIANT IS TO THE CONTROL OF EXPENDIANT IN THE CONTROL OF EXECUTED IN THE CONTROL OF THE CON	(or "Foe Address" indication for record) etached Use of a part record) etached Use of a part record) etached Use of a part record of the control of the USPTO or is being admit the use of the USPTO or is being admit the USPTO. The part of the United Subsection for (if recorded by 35 USPS Funds to the USPTO. These will vie to the USPTO. The wall vie to the wall vie to the USPTO. The wall vie to the USPTO. The wall vie to	form a Customer a Cust	single firm (series strongs or signs) registered potent at it is listed, so some with the potent of	in a manufacture of the form in Nr. 15 TATE ON 15 T	the inner of a registrated as of up to 2 and up to 2 a	Rechard Le ZA C C C appropriate who there private group there private group to be application to copy of this form 0 to application to CE ARTMENT OF	M. Bo of Areas, E. A. S.	Erg

tterney Docket No.: 5637.200-US

PATENT

DE 17 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Buch-Rasmussen et al.

Scrial No.: 09/348,536

Group Art Unit: 3763

Filed: July 7, 1999

Examiner: Sirmons

Confirmation No: 5366

For: Medication Delivery Device

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Attn: Official Draftsperson Commissioner for Patents Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

- I. Submission of Formal Drawings
- I Sheet of Formal Drawings

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Attn: Official Draftsperson Commissioner for Patents Washington, DC 20231

on December 12, 2002.

Rashida Haii

(name of person mailing paper)

(signature of person mailing paper

Atterney Docket No.: 5637.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Buch-Rasmussen et al.

Serial No.: 09/348,536

Group Art Unit: 3763

Filed: July 7, 1999

Examiner: Sirmons

Confirmation No. 5366

For: Medication Delivery Device

SUBMISSION OF FORMAL DRAWINGS

Commissioner for Patents Washington, DC 20231

Sir:


Applicants submit herewith 1 sheet of formal drawings, containing Figures 2A, 2B and 3 for the above-captioned application. The formal drawings are being filed in response to the request contained in the Attachment to the Notice of Allowande and Issue Fee Due, mailed September 20, 2002, and should be substituted for the corresponding sheets of informal drawings of the originally filed application.


Respectfully submitted,

Date: December 12, 2002


Marc A. Began, Reg. No. 48,829 Novo Nordisk Pharmaceuticals, Inc. 100 College Road West

Princeton, NJ 08540 (609) 987-5800





PLEASE DO NOT SCAN



THESE PAPERS

Attorney Docket No.: 5637.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE EXPRESS MAIL CERTIFICATE

Box Patent Application Assistant Commissioner for Patents Washington, DC 20231

> Re: U.S. Patent Application for "Medication Delivery Device" Applicants: Buch-Rasmussen et al.

Sir:

Express Mail Label No. EL293688877US

Date of Deposit July 7, 1999

I hereby certify that the following attached paper(s) or fee

- 1. Filing Under 37 C.F.R. 1.53(b) (in duplicate)
- 2. Patent Application
- 3. Preliminary Amendment
- 4. Unexecuted Combined Declaration and Power of Attorney

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington, DC 20231.

Miriam Kelly

(Name of person mailing paper(s) or fee)


(Signature of person mailing paper(s) or fee)

Mailing Address:

Novo Nordisk of North America, Inc. 405 Lexington Avenue, Suite 6400 New York, NY 10017 (212) 867-0123

What is claimed is:

The Helbert	/	·				Sheet 1 of 1
	us. Depart Patent am	THENT OF COMMERCE O TRADEMARE OFFICE	Alty. Docket No. 5637.20	0-US	Serial No. 09/3	348,536
	Diformation disclosur Statement by applican		Applicant Buch-Rasmu	ssen et al.		
	(Use several shoots if accessory)	Filing Date July 7, 1999		Group 3734	
AITEM & TRANS		U.S. PATI	ENT DOCUMENTS			· · · · · · · · · · · · · · · · · · ·
EXAMINER DUTTAL	DOCUMENT NUMBER	DATE	NAMB	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
145	4,936,833	6/26/90	Sams	_/		
	5,226,895	7/13/93	Harris			
	5,549,575	8/27/96	Giambattista et al.	_		- -, -
	5,688,251	11/18/97	Chanoch			·
	4,973,318	11/27/90	Holm et al.	اخر		
<u> </u>						
,	- 1 	FOREIGN PA	TENT DOCUMENTS			
	DOCUMENT		•			TRANSLATION
	NUMBER	DATE	COUNTRY	CLASS:	SUBCLASS	YES NO
165	EP 0 688 571	12/27/95	EPO'			
	WO 95/13842	5/26/95	WIPO		<u> </u>	
	WO 94/21213	9/29/94	MIBO		<u> </u>	
	WO 97/49620	12/31/97	MIBO	-	Anr Sal	
	WO 96/02290	2/1/96	WIPO			-
	OTHER DO	COMENTS (Including	Author, Title, Date, Pertine	nt Pages, Etc.	CEN ER	VIII.
		·············			. 40	<u> </u>
			·	-	700	
				,		
,			×			
			·		<u> </u>	<u>. </u>
				· · · · ·	· · · · · ·	
			•			
	<u> </u>					
		<u> </u>	<u> </u>		•	
EXAMPLE	ļ. ļ					
	mon		DATE CONSIDERED	19/01	,	·
EXAMINER: Latini	l citation considered, whether actuals copy of this form with	or not citation is in con next communication to	elocmance with MPEP 609; I applicant	Draw line the	only catation it o	ot in conformance
	<u> </u>		•		7	





SKADDEN, ARPS, SLATE, MEAGHER & FLOM Four Times Square New York, NY 10036-6522

Telephone: (212) 735-3020 Facsimile: (917) 777-3020

Date: October 25, 2001

Applicant(s):

Buch-Rasmussen et al.

Serial No.

09/348,536

Examiner: Simons, K.

Filed

July 7, 1999

Art Unit: 3763

Title

Medication Delivery Device

AMENDMENT TRANSMITTAL AND REQUEST FOR EXTENSION OF TIME

Assistant Commissioner For Patents Washington, DC 20231

Sir:

I hereby certify that this paper is being deposited with the United States Postal Service, as first class mail, in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231, on October 25, 2001.

Reg. No. 28,538

October 25, 2001

Transmitted herewith is an AMENDMENT in the above-identified

application.

No additional fee is required.

11/23/2002 HMARZII 00000032 192385 09348536

4 FC:115

110.00 CH

B#!				
	· La dena		- و د سر	Docket No. 5637.200-US
		2.	()	The fee has been calculated as shown below:
			Claims Total: Indeper	remaining Prior Paid Claims Extra Rate Fee minus (at least 20) @ \$18 = \$ adent minus (at least 3) .= @ \$80 = \$ TOTAL ADDITIONAL FEE: \$
1121121	1	3.	(X)	An extension of time to respond to the PTO Communication dated <u>June 27, 2001</u> is hereby requested. The required fee is indicated below:
	•			Within first month: (X) \$110 Within second month (.) \$390 Within third month () \$890 Within fourth month () \$1,390
1		4.	()	The Amendment includes an Information Disclosure Statement. Enclosed is Form PTO-1449 and copies of reference(s).
Transfer of the second	•	5.	(X)	The Commissioner is hereby authorized to charge the amount of \$110.00 representing (a) additional claims fee (\$); (\$) the extension fee (\$110); and (c) the fee for filling an Information Disclosure Statement (\$) to deposit account No. 19-2385. A copy of this sheet is enclosed for such purpose.
		6.	(X)	In the event that an extension of time is required and applicant has inadvertently overlooked the need to request a petition and file the fee, the applicant hereby petitions for such extension of time. The Commissioner is authorized to charge the required fee to deposit account No. 19-2385. A copy of this sheet is enclosed for such purpose.
The second second		7.	(X)	The Commissioner is hereby authorized to charge payment of any additional fees required in connection with this application, and credit any overpayment, to deposit account No. 19-2385. A copy of this sheet is enclosed.
A THE PARTY OF THE				Skadden, Arps, Slate, Meagher & Flom By Robert B. Smith Registration No. 28,538 Attorneys for Applicant(s) (212) 735-3020



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):

Buch-Rasmussen et al.

Serial No.

09/348,536

Examiner: Simons, K.

Filed

July 7, 1999

Art Unit: 3763

Title

Medication Delivery Device

I hereby certify that this paper is being deposited with the United States Postal Service, as first class mail, in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231, on October 25, 2001.

Robert B. Smith

Reg. No. 28,538

October 25, 2001

October 25, 2001

RESPONSE TO OFFICE ACTION

Assistant Commissioner For Patents Washington, DC 20231

Sir.

The applicants respectfully request reconsideration of the rejection of claims 2-7, 10-12, and 26-28, mailed on June 27, 2001. The applicants respectfully request, in particular, that the Examiner reconsider the assertion that the cartridge holder element 300 of the cited Chanoch patent can be deemed to be part of a


"molded cartridge" element as recited in claim 26. In requesting reconsideration, the applicants note that the Examiner's position that the cartridge holder 300 of Chanoch. can be deemed to be part of a "molded cartridge" as recited in claim 26 is inconsistent with the Examiner's interpretation of DiBiasi U.S. patent No. 6,146,361, set forth in the final rejection dated January 17, 2001. In previously applying DiBiasi to claim 26, the Examiner asserted that the element in DiBiasi corresponding to the "molded cartridge" in claim 26 constitutes the cartridge 22 only, and not the cartridge holder.

Claim 26 claims a "cartridge assembly" that includes a "molded cartridge" with a stopper. Claim 26 further requires that the "cartridge assembly" includes two coupling means for engaging, respectively, a needle assembly and the dosing assembly. Finally, claim 26 recites that "at least one of said coupling means is unitarily molded with the cartridge" (i.e., at least one of the coupling means must be unitarily molded with the cartridge, and not merely associated with the cartridge assembly).

Chanoch U.S. patent No. 5,688,251 discloses a pen type syringe which includes a "cartridge holder assembly 300" that includes "a molded housing 304." Col. 5, lines 50-51. A "medication cartridge 350 [is] securely retained in housing 304." Col. 6, lines 1-2. More particularly, a "cap 354 extends between housing 304 and cartridge 350 for securely and permanently holding medication cartridge in housing 304." Col. 6, lines 3-8. Finally, a needle cannula assembly 500

has a mounting hub 504 which is "threadingly engageable with the cap 354." Col. 6, lines 15-20.

The disclosure that, but for the cap 354, the cartridge 350 can be separated from the cartridge holder housing 304 means that the housing 304 and cartridge 305 are separate elements, which are mechanically coupled to one another during some stage of the assembly process. Thus, if Fig. 2 of Chanoch were modified to show the parts of the syringe prior to such assembly, it would be as follows:



Thus, as evident from the Chanoch specification, the cartridge holder 300 is not molded unitarily with the cartridge 350 - they are separate elements.

As discussed above, claim 26 recites two coupling means for engaging, respectively, a needle assembly and the dosing assembly, and recites that "at

least one of said coupling means is unitarily molded with the [molded] cartridge." Chanoch discloses two coupling means: (1) internal threads 303 formed in the barrel of the cartridge holder 300 (which engage cooperating threads on the pen body 100), Col. 5, lines 55-57; and (2) threads on the external surface of the cap 354 (which engage internal threads provided in the needle hub 504). Col. 6, lines 18-20. Thus, Chanoch disclose two coupling means for engaging, respectively, a needle assembly and a dosing assembly. However, in Chanoch both such coupling means are provided on the cartridge holder, not on the "molded cartridge" itself. Thus, Chanoch does not anticipate or suggest claim 26.

The commonly owned Chanoch and DiBiasi patents both show a syringe having a cartridge holder element which screws onto a pen body. Both the cartridge holder of Chanoch and the cartridge holder of DiBiasi receive a separate cartridge. The difference between Chanoch and DiBiasi is that, in Chanoch, once the cartridge is inserted in the cartridge holder barrel, it cannot be removed. Thus, when the cartridge is empty, the user must replace both the cartridge and the cartridge holder. In contrast, DiBiasi allows the cartridge to be removed from the cartridge holder when empty, so that only the cartridge, and not the cartridge holder needs to be replaced. This difference is immaterial relative to the claims of the present application.

As discussed in the applicants's Response After Final Rejection dated June 11, 2001, in applying DiBiasi to claim 26, the Examiner did not consider the

cartridge holder to be part of the claimed "molded cartridge." Rather, the Examiner deemed the cartridge 22 of DiBiasi to correspond to the "molded cartridge" of claim 26, and treated the "cartridge retainer" 10 of DiBiasi to constitute a separate element. Final Office Action, Paragraph 2.

The cartridge holder and cartridge shown in DiBiasi are very similar to the cartridge holder and cartridge shown in Chanoch, except that, in Chanoch, the cartridge is permanently retained in the cartridge holder (and insofar as the cartridge holder barrel in Chanoch has internal threads to engage the pen body) Thus, it is inconsistent for the Examiner to deem the cartridge (but not the cartridge holder) to constitute a "molded cartridge" when interpreting DiBiasi, and yet to deem both the cartridge and the cartridge holder to constitute a "molded cartridge" when interpreting Chanoch.

For such reason, the applicants do not believe that the combination of the cartridge 350 and the cartridge holder 300 of Chanoch can properly be deemed to correspond to a "molded cartridge." Certainly, a person skilled in the art would not deem a cartridge holder to be part of a molded cartridge, as evidenced by the fact that the Chanoch specification clearly differentiates between a cartridge and a cartridge holder. See, Hoechst Celanese Corp. v. BP Chems. Ltd., 78 F.3d 1575, 1578, 38 U.S.P.Q.2d 1126, 1129 (Fed. Cir. 1996) (stating that a claim term is to be given the meaning that it would be given by persons experienced in the field of invention).

Because the rejection of the claims hinges on the assertion that the cartridge holder 300 of Chanoch is part of a "molded cartridge," the applicants respectfully request reconsideration and allowance of the pending claims.

Respectfully submitted,

Robert B. Smith

PTO Registration No. 28,538

Attorney for applicant(s)

(212) 735-3020

	PATENT A			TERMINATION 1998		RD .			•			
CLAIMS AS FILED - PART I SMALL ENTITY OTHER THAN (Column 1) (Column 2) TYPE OR SMALL ENTITY												
-)R		olumn 1) R FILED	NUMBER				וריי		FEE		
_	<u>"</u>	140,000			RATE		4	RATE	_			
A	SIC FEE					<u> </u>	380.00	OR		760.00		
С	TAL CLAIMS	1 2	minus 2	0= • 5		X\$ 9=		OR	X\$18=	90		
Ľ	EPENDENT CL	AIMS 6	minus:	3 = *		X39=		OR	X78=			
L	LTIPLE DEPEN	DENT CLAIM PI	RESENT			+130=		OR	+260=			
ŕ	the difference.	in column 1 is	ess than ze	ro, enter "0" in o	olumn 2	L			TOTAL	8/80		
'	•					TOTAL	•	Jun				
	C	LAIMS AS A	MENDED	- PART II (Column 2)	(Column 3)	SMAL	LENTITY	OR	SMALL			
_		(Column 1) CLAIMS	<u> </u>	HIGHEST	(CORDINAL ST		ADDI-	7		ADDI-		
	-,	REMAINING AFTER AMENDMENT		NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	TIONAL		RATE	TIONAL		
	Total	*	Minus	p.st	=	X\$ 9=		OR.	X\$18=			
	Independent	*	Minus	***	=	X39=		OR	X78=			
_	FIRST PRESE	NTATION OF MU	JUNPLE DEP	ENDENT CLAIM		+130=		OR	+260=			
						TOT/		4	20074			
				•		ADDIT. FE		Юн	ADDIT. FEE			
_		(Column 1) CLAIMS		(Column 2) HIGHEST	(Column 3)		7 :	9 1				
2		REMAINING	i i	NUMBER	PRESENT	RATE	ADDI- TIONAL	1	RATE	ADDI- TIONAL		
	:	AFTER AMENDMENT		PREVIOUSLY PAID FOR	EXTRA	PALE	FEE		RAIL	FEE		
	Total	•	Minus	**	□	X\$ 9=		OR	X\$18=			
	independent	*	Minus	***	=	X39=	1	OR	X78=			
_	FIRST PRESE	NTATION OF MU	JLTIPLE DEF	ENDENT CLAIM			1	1		\vdash		
				•		+130=		OR	+250=			
						ADOIT, FE		OR	TOTAL ADDIT, FEE			
		(Column 1)		(Column 2)	(Column 3)							
,		CLAIMS REMAINING		HIGHEST NUMBER	PRESENT		ADDI-	1		ADDI-		
		AFTER		PREVIOUSLY	EXTRA	RATE			RATE	TIONAL		
	Total	AMENDMENT	Minus	PAID FOR	<u>.</u>	V# 0	FEE		X\$18=	FEE		
	Independent	*.	Minus	***	=	X\$ 9=	1	OR	 			
•		<u> </u>	JUTIPLE DEF		1	X39=		OR	X76=			
	FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM											
	1111011	+130= OR +260=										
•	f the entry in colu			min 2, write "0" in co S SPACE is less the		TOTA ADDIT, FE		OR.	TOTAL ADDIT. FEE			

(12) United States Patent Buch-Rasmussen et al.

(10) Patent No.:

US 6,562,011 B1

(45) Date of Patent:

May 13, 2003

(54)	MEDICA:	TION DELIVERY DEVICE
(75)	Inventors:	Thomas Buch-Rasmussen, Gentofte (DK); Benny Munk, Hvidorre (DK); Jens Ulrik Poulsen, Virum (DK);

Jens Ulrik Poulsen, Virum (DK); Henrik Ljungreen, Ballerup (DK); Peter Møller Jensen, Horsholm (DK); Jens Møller Jensen, Copenhagen (DK)

(73) Assignee: Novo Nordisk A/S, Bagsvaerd (DK)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: 09/348,536 (22) Filed: Jal. 7, 1999

Related U.S. Application Data

(60) Provisional application No. 60/098,702, filed on Sep. 1, 1908

(30) Foreign Application Priority Data

	1, 8, 1998 17, 1998			
(51)				
(52)	U.S. CL	**********	** ** *** *** *** *** *** *** *** ***	604/232
(58)	Field of	Search	60	4/200-201.
			604/22	8, 232-234

(56) References Cited

U.S. PATENT DOCUMENTS

4.597.753	Α	•	7/1986	Turley 604/61
4,865,591	Α	٠	9/1989	Sams 604/186
4,936,833	Α		6/1990	
4,973.318			11/1990	Holm et al.
5.137.511		ŧ		Reynolds 604/68
5,226,895	Ä		7/1993	Harris
5,364,369	Α	•		Reynolds 604/187
5,549,575	A			Giornhattista et al

5.554,125	A		9/1996	Reynolds		*******	604/187
5,688,251	A		11/1997	Chanoch			
6,146,361	A	e	11/2000	DiBlasi c	ı aL	****	604/232

FOREIGN PATENT DOCUMENTS

EP	0 688 571	12/1995
WO	WO 94/21213	9/1994
WO	WO 95/13842	5/1995
WO	WO 96/02290	2/1996
WO	WO 97/49620	12/1997


* cited by examiner

Primary Examiner—Brian L. Casler
Assistant Examiner—Kevin C. Sirmons
(74) Attorney, Agent. or Firm—Marc A. Began, Esq.;
Richard W. Bork, Esq.; Reza Green, Esq.

(57) ABSTRACT

The present invention relates to a medication delivery device comprising a cartridge assembly, a dosing assembly and optionally a needle assembly. The carridge assembly comprises a cartridge having a stopper adapted to receive a funger means. Furthermore, the cartridge assembly has one end sealed with a pierceable sealing, said end comprising coupling means for engaging a needle assembly, and another end comprising coupling means for engaging the dosing assembly. At least one of the coupling means of the cartridge assembly is unitarily moulded with the cartridge. The dosing assembly comprises a plunger means and has coupling means for engaging the cartridge assembly and the dosing assembly are coupled together for delivering selected doses of medication. The cartridge is preferably moulded from a plastic material, such as a transparent material, and may be housed in a cartridge housing for protection of the cartridge. The coupling means may be selected from threaded locks, snap locks, hinged locks, or bajonet locks. The medication delivery device is especially suitable for delivering insulin, growth hormone or other medicines.

7 Claims, 2 Drawing Sheets



U.S. Patent

May 13, 2003

Sheet 1 of 2

US 6,562,011 B1





Fig. 1



US 6,562,011 B1

1

MEDICATION DELIVERY DEVICE

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority under 35 U.S.C. 119 of 5 Danish application nos. PA 1998 00909 filed Jul. 8, 1998 and PA 1998 01500 filed Nov. 17, 1998, and U.S. provisional application No. 60/098,702 filed Sep. 1, 1998, the coments of which are fully incorporated herein by reference.

The present invention relates to a medication delivery device having a cartridge and a dosing assembly coupled together for delivering selected doses of medication, wherein at least one of the coupling means of the cartridge is unitarily moulded with the cartridge.

BACKGROUND

Some medication, such as insulin is self-administered. The typical diabetes patient will require injections of insulin several times during the day. The required insulin dose will away from patient to patient, and will for each patient often also vary during the day. Each patient will often establish a regimen for the insulin administration adjusted to his or her insulin need as well as lifestyle. Medication delivery pens have been developed to facilitate the self-administration of medication, such as insulin.

One prior art medication delivery pen includes a pen body assembly comprising a medication cartridge and a plunger device. A needle assembly may be connected to the pen body assembly. The medication is delivered by moving or pressing a plunger in the direction of the needle assembly thereby delivering the medication. When the medication in the cartridge is exhausted the pen body assembly is discarded. Depending on the medication needs for each individual the medication in the cartridge will last for several days. During 35 this period the needle assembly will often have to be replaced by a new assembly or new needle due to increasing bluminess of the needle making injections painful for the patient.

More recent developments have revealed medication delivery pens, wherein the cartridge holder assembly can be disassembled from the pen body assembly after the medication therein has been exhausted, discarded and replaced by a new medicine-containing cartridge assembly.

An example of this is shown in EP 0 688 571 disclosing a medication delivery pen having a reusable pen body assembly and a disposable cartridge assembly that are threadedly engageable with one another. The cartridge assembly comprises a cartridge, a cartridge housing, a cap between the distal end of the cartridge and the housing, securing the cartridge in the housing and being adapted for engagement with a needle assembly. Furthermore, the cartridge comprises a plunger within the cartridge. The reusable pen body assembly is coupled through a threaded coupling to the cartridge housing. Thus, the total number of parts comprising the prior at cartridge assembly is high.

It is an object of the present invention to provide a medication delivery device wherein the amount of parts of the cartridge is minimized.

SUMMARY OF THE INVENTION

Accordingly, the present invention relates to a medication delivery device comprising a carridge assembly, a dosing assembly and optionally a needle assembly.

said cartridge assembly having one end sealed with a pierceable sealing, said end of the cartridge assembly

2

comprising coupling means for engaging a needle assembly, and another end comprising coupling means for engaging the dosing assembly, said cartridge assembly further comprising a cartridge wherein at least one of the coupling means of said cartridge assembly is unitarily moulded with the cartridge, the cartridge further comprising a stopper adapted to receive plunger means, and

said dosing assembly comprising plunger means has coupling means for engaging the carridge assembly, and said plunger means is adapted to engage the stopper of the carridge when the dosing assembly is coupled to the carridge.

The unitarily moulded (coupling or coupling ensure that the coupling is not accidentally released from the cartridge during use and storage. Also, the above-described medication delivery device has fewer parts that the prior art devices because at least one coupling means is moulded unitarily with the cartridge. Thereby the costs involved in the production and assembling of the device are reduced, and the device is more economical which is an important feature for a disposable device.

regimen for the insulin administration adjusted to his or her insulin need as well as lifestyle. Medication delivery pens have been developed to facilitate the self-administration of medication, such as insulin.

The medical delivering device may either be manufactured as a disposable device which is sold pre-filled with the insulin or it may appear as a durable medical delivering device which is sold pre-filled with the insulin or it may appear as a durable medical delivering device which is sold pre-filled with the insulin.

In a preferred embodiment the dosing assembly is reusable and the cartridge assembly is disposable, and accordingly, a second aspect of the present invention is a medication delivery device wherein the dosing assembly is releasably coupled to the cartridge assembly. The medication delivery device is preferably constructed

The medication delivery device is preferably constructed so as to ensure that the plunger means abuts on the stopper during use of the device, such as attaching and releasing the needle assembly. It is understood that the plunger means must disengage the stopper when the carbridge assembly is deliberately released from a reusable dosing assembly because the medication in the cartridge has been exhausted and the carbridge assembly is to be discarded. In this situation the plunger means is to be retracted to the dosing assembly before assembling the device with a new carbridge assembly.

Securing the abutment of the plunger means on the stopper during use of the medication delivery device, in particular when the needle assembly is coupled to and/or decoupled from the cartridge assembly, may be carried out by a variety of means. In a preferred embodiment the abutment is secured by preventing the cartridge assembly from being inadvertently released from the dosing assembly.

In particular, when the cartridge assembly is released from the dosing assembly through a movement including an axial movement, such as through a threaded coupling, it is preferred that the means for releasably coupling the needle assembly and the cartridge assembly together are such that the coupling and/or decoupling of the needle assembly cannot cause an axial movement of the cartridge assembly with respect to the dosing assembly. Thus, in that respect examples of the preferred couplings between the needle assembly and the cartridge assembly include releasable snap locks. Another preferred embodiment includes a safety on the coupling between the dosing assembly and the cartridge assembly, such as hinge on the coupling or a threaded coupling releasable only after exerting an axial pressure on the coupling.

A second aspect of the present invention is a cartridge assembly for use in a medication delivery device, said

US 6,562,011 B1

carridge assembly having one end sealed with a pierceable sealing, said end of the cartridge assembly comprising coupling means for engaging a needle assembly, and another end comprising coupling means for engaging the dosing assembly, said cartridge assembly further comprising a cartridge wherein at least one of the coupling means of said cartridge assembly is unitarily moulded with the cartridge, said carridge further comprising a stopper.

The cartridge assembly may further comprise a cartridge housing for protecting the cartridge in use. Furthermore, when the cartridge is moulded unitarily with one coupling means the carridge housing may comprise the other coupling means. Accordingly, in one embodiment of the invention the housing of the cartridge assembly comprises cou-pling means for coupling the cartridge assembly to the dosing assembly, preferably the coupling means is moulded unitarily with the housing. The cartridge is arranged within the cartridge housing. The cartridge housing may be nonreleasably attached to the cartridge, once the cartridge is arranged in the housing, whereby the housing is disposed with the cartridge. In another embodiment the housing is 20 reusable and the cartridge is arranged releasably in the

In a preferred embodiment all the coupling means of the cartridge assembly are unitarily moulded with the cartridge. Thereby, it is possible to construct the cartridge assembly 25 without the housing providing a carridge assembly with even fewer parts.

The coupling means of the cartridge assembly may be for any suitable coupling, preferably a releasable coupling. Examples of the coupling are snap locks, such as snap locks 30 with guidewire and sideways snap locks, snap locks released through threads, bajonet locks, luer locks, hinged locks, threaded locks and any suitable combinations thereof.

The coupling means unitarily moulded with the cartridge are preferably external coupling means, such as an external threaded coupling.

In particular the coupling means for engaging to the dosing means may be an external threaded coupling.

The cartridge may be moulded from any material suitable for medical containers. The cartridge is preferably moulded 40 from a plastic material, e.g. by injection moulding. A suitable choice of material allows the cartridge to be at least partly transparent, whereby the user can see whether content, such as liquid is left in the cartridge. In a preferred embodiment the cartridge is totally transparent giving the 45 user a greater possibility of inspecting the content of the cartridge.

By using a plastic material as compared to the usual glass material a great advantage is achieved in the production lines. Normally a significant quantity of the produced glass 50 carridges will be spoiled in the lines due to breakage. however the loss is greatly reduced by the use of plastic cartridges. Furthermore, the risk of small loose glass particles in the carridges have been eliminated.

Also, by moulding the coupling(s) unitarily with the 55 cartridge a very precise coupling mechanism may be obtained, since no further steps are to be taken to attach coupling means to the cartridge.

The carridge may be of any suitable form, such as a cylinder. The cylinder may be constructed with various 60 combinations of circular or non-circular inner and outer cross-section. In another embodiment the cartridge may be box-shaped having essentially rectangular or triangular

The stopper is in sliding fluid tight engagement in the 65 carridge. The stopper is preferably made of plastic and/or rubber material.

The flexibility of the cartridge wall is not critical, however if the cartridge is too flexible the function of the stopper may be impaired. Mostly, the cartridge is made of a material only slightly flexible to non-flexible.

In order to enforce and strengthen the cartridge wall the cartridge may be integrally moulded with reinforcements. Thereby, the necessity of a protective housing may be obviated. Furthermore, a scale may be integrally moulded with the cartridge wall providing the user with a measure for the medication used and left.

In a most preferred embodiment the cartridge assembly is comprised only of a cartridge being sealed in one end with a sealing, being unitarily moulded with all couplings means

and comprising a stopper.

In a cylindrical cartridge the two couplings of the cartridge assembly are generally opposing each other having the same axis. However, the coupling for engaging with the dosing assembly being separate from coupling for engaging the needle assembly may be arranged so that their axis are in any angle with respect to each other, such as

perpendicular, or even parallel, but not overlapping.

Another aspect of the present invention is a cartridge being at least parily filled with liquid medication, such as

In another embodiment the invention relates to a medication delivery device for transferring medication from the cartridge into a syringe with a needle. In this embodiment the coupling means for engaging the needle assembly may be replaced by coupling means for engaging the syringe, or coupling means for both may be provided. The coupling means may be a syringe holder, for example a cylinder coupled to the cartridge comprising a central bone for receiving the syringe. The syringe is coupled to the cartridge having the needle piercing the sealing. By activation of the dosing means the metered amount of medication is driven into the syringe. The syringe is then ready for injection after being removed from the cartridge

DRAWINGS

FIG. 1 is an exploded perspective view of the medication delivery device.

FIG. 2 is a cross-sectional view showing part of the medication delivery device, 2a immediately after ass bling before the first injection, and 2b after some time of use.

FIG. 3 is a cross-sectional view showing the cartridge before assembling of the medication delivery device.

DETAILED DESCRIPTION OF THE INVENTION

A medication delivery device in accordance with the present invention is identified generally by the numeral 20 in FIGS. 1 and 2. Medication delivery device 20 includes a dosing assembly 6, and cartridge assembly 1, a needle assembly 16 and a cap 14.

The dosing assembly 6 is illustrated in FIGS. 1 and 2. It is understood, however, that the dosing assembly 6 according to the invention may be any suitable dosing unit including plunger means, and accordingly, that variations from the depicted embodiment may be provided, and are considered to be within the scope of this invention. In the depicted embodiment the dosing assembly 6 includes a cylindrical housing surrounding the plunger means 17 of the dosing unit and baving opposed proximal and distal ends.

In one aspect of the invention the plunger means comprises a rod element 7 which is adapted to engage the stopper 4 of the cartridge assembly 1. The rod element 7 advances

US 6.562,011 B1

axially into the cartridge 5 during injections. The dosing assembly may have any suitable driving means for advancing the rod element 7.

The dosing unit 6 preferably also comprises scale means 10 indicating the dosing quantity selected by activating the dose setting means 9 for defining specified selected doses of medication to be delivered. The selected dose may be delivered by actuating the actuator button 18. The actuator button is part of the driving means of the dosing assembly exerting its force on the rod element 7.

The dosing assembly further comprises coupling means 8 adapted for engagement with the cartridge assembly. The coupling means 8 may be internal or external couplings. In a preferred embodiment the coupling 8 is an internal coupling.

The carridge assembly 1 is illustrated in FIGS. 1 and 2, and in greater detail in FIG. 3. In FIG. 1 cartridge assembly I includes a moulded cartridge 5 extending from proximal end 21 to distal end 22.

provided coupling means 2 for releasably mounting a needle assembly 11. At the proximal end 21 of the cartridge assembly 1 is provided coupling means 3 for mounting a dosing assembly 6. The coupling means are as described

Cartridge 5 also comprises a stopper 4 in sliding fluid tight engagement within said cartridge 5. The stopper 4 is adapted to receive the plunger means, such as a rod element 7 of the dosing assembly 6. The rod element 7 is adapted to exert an axial movement of the stopper 4 towards the sealed end 22 30 of the carridge 5.

The cartridge assembly 1 may further comprise a housing for protecting some or all of the cartridge 5. When the cartridge assembly I includes a housing, one of the couplings 2, 3 of the cartridge may be moulded unitarily with 35 the housing.

Instead of the protective housing the carridge 5 may have integrally moulded reinforcements of the cartridge wall.

The depicted carridge 5 is cylindrical having couplings 2, 3 at opposed ends. However, the cartridge may obtain any suitable form and the cross-section may be circular or non-circular, such as substantially triangular or oval.

The device according to the invention may include a protective cap 14 that is removably mounted over the 45 cartridge assembly I and/or the needle 11 and which is removed before injection of the medication in the cartridge 5. The cap further ensures that the content of the cartridge is protected against sunlight,

Referring to FIG. 3 the coupling means of the cartridge 50 are shown in greater detail. The coupling means 3 is an external thread, whereas the coupling means 2 is a recess for a snap lock of the needle assembly. Both coupling means are moulded unitarily with the carridge.

The various parts of the medication delivery device are 55 advantageously made of plastics, e.g. by injection moulding.

The medication delivery device 20 may further comprise any appropriate needle assembly 11, such as a double ended needle 13 having opposed proximal and distal points and a lumen extending axially therebetween.

A mounting hub 12 is engaged on the needle 13 and is removably connected to the coupling means 2 at the needle end of the cartridge assembly. The relative location of the mounting hub 12 ensures that the proximal point of the needle 13 will pierce the sealing when the mounting hub 12 65 opposed. is engaged with the coupling means 2 on the cartridge assembly 1.

The needle assembly 11 may further comprise a removable shield or cap 15 for protecting against accidental needle

The device according to the invention is suitable for delivering pre-set dosages of insulin, it is however understood that the device is suilable for the injection of pre-set dosages of other liquids.

In use the user will set the dose by means of the dose 10 setting means 9. Before activating the actuator button 18 the cap 14 must be removed from the carridge assembly] whereby the device 20 is prepared for an injection. The injection is effected by activating the actuator button 18, which again will cause the stopper 4 to be moved towards the sealed end 22 of the calmidge 5, thereby delivering the desired pre-set dosage. A subsequent dosage of medication will be set in exactly the same manner as described above. However, for such a subsequent dosage, the rod element 7 and the stopper 4 will be in a partly advanced position as

At the distal end 22 of the cartridge assembly 1 is 20 starting point. Dose setting and injections can be carried out until all of the medication has been used.

What is claimed is:

1. A medication delivery device comprising a cartridge assembly having opposite ends and a dosing assembly for setting a desired dose and acting on the cartridge assembly to cause the desired dose to be delivered, wherein:

the cartridge assembly includes a molded cartridge and a stopper disposed in the cartridge, wherein one end of the cartridge assembly is sealed with a pierceable sealing, wherein the one end includes a first coupling means for releasably mounting a needle assembly having a skin-piercing needle, and wherein the other end of ing a skin-piercing acetile, and wherein the other end of the cartridge assembly includes a second coupling means for engaging the dosing assembly, wherein at least one of the coupling means is unitarily molded with the cardidge, and wherein the dosing assembly includes a housing, a plunger, and a mechanism for setting a desired dose and for moving the plunger relative to the housing in an axial direction for administering a set dose, and wherein the dosing assembly housing includes a coupling member for engaging the second coupling means of the cartridge assembly for securing the housing against axial movement relative to the carnidge assembly such that the plunger engages the stopper for moving the stopper in response to the plunger movement wherein the at least one coupling means of the cartridge assembly is a threaded coupling and wherein the second coupling means is an external threaded coupling.


- 2. The medication delivery device according to claim 1, wherein both said coupling means of said cartridge assembly are unitarily molded with the cartridge.


 3. The medication delivery device according to claim 1.
- wherein the said at least one coupling means of said car-tridge assembly is an external coupling.


 4. The medication delivery device according to claim 1.
- wherein the cartridge is molded of a plastic material.

 5. The medication delivery device according to claim 4. wherein the cartridge is at least partly transparent.

 6. The medication delivery device according to claim 1.
- wherein the dosing assembly further comprises a scale.
- 7. The medication delivery device according to claim 1, wherein the coupling means of the cartridge assembly are







			
7.5		. 😹	<u> </u>
PAIENI APPLICATION	19/26227		
		TALS MTW	
09348536	07/07/99		
	CONTENTS		ž.
	Date received	Date received	Š.
	(incl. C. of M.)	(Incl. C. of M.)	
	or Date Mailed	or Date Mailed	
1. Applicationpapers.	/ / 42		
	8/5/99 43.	T	
3 Drisioned Dec	15 10 19		
-130C+Surcharge	2000		ă,
Mulmetra	1.7.99 45	<u> </u>	
5. Yng Cymol B	<u>-7.7.99</u> 46		
of the Bolish	3/9/00 H 41.	<u> </u>	9
La Tertion	4-4-00 48.	L	
Mr (Box)	04/26/00 4 7/kg		
	A/1/00 50.		
9. CAN 0.00		<u> </u>	
10. Key Par CFK	1/31/00 51.		
11. Phatimas	10/21/0 52. · · · · · · · · · · · · · · · · · · ·		
12 Futt Cl	10/27/60 53.		
FINAL REJECTION	6111/91 54.	<u> </u>	
y Got Ima	(a - 13,01 ss.		
the Reg for Peron lies	Ho 13-11 56.		
Cale Land	16-141		3
PELECTION -	97040 57		
Joseph Colors	58		
THE EXTONITY TO	11902 59.	<u> </u>	
19 Key For Vecoro	11402 60.		
26 Gord CyB)	4/50/02 HSc 161.	ļ·	
CAY/LOND (N.F.)	8/20/02 62	· · · · · ·	
The second of th	9-20-62 63.		
QUERY/ 10/21/0	1 /	· ·	
24	11/12/02		
24 RED FURCUER		<u> </u>	
25. Paronly	02-12-03 66.	<u> </u>	
0726 85B CAG OF ADD	12/18/02 67		
THE SO P. 27. TOTAL CONTROL (A. STE)	5t 12t 0268.		
28.	69/		
	70.		
29			
30			
31	72		
32	73		
33	74		
34	75. <u></u>		
2.56.0. 35	76		
37		 1	
38		<u> </u>	
39	80.	 	
40	81,	<u> </u>	200
41		<u> </u>	
	(LEFT OUTSIDE)	- 2	
	(LEF-1 COTSIDE)		
	The Market Control of the second of the Control of	ter de la como solator e parte de la como	
			